N,N-Dimethylphenylethylamine
Mechanism of Action +
### The Phenethylamine Backbone and Structural Modifications
N,N-Dimethylphenylethylamine (N,N-DMPEA) belongs to the broad class of substituted phenethylamines, a group of compounds characterized by a phenyl ring attached to an amino group via an ethyl chain. This foundational structure is shared by endogenous trace amines (like phenylethylamine, or PEA), classical neurotransmitters (like dopamine and norepinephrine), and various synthetic stimulants. The critical structural divergence of N,N-DMPEA lies in the N,N-dimethylation—the attachment of two methyl groups to the terminal nitrogen atom.
In endogenous PEA, the unsubstituted amine is highly susceptible to rapid oxidative deamination by the enzyme monoamine oxidase B (MAO-B). This rapid metabolism results in a biological half-life of mere minutes, rendering oral ingestion of standard PEA largely ineffective for sustained systemic effects unless co-administered with an MAO inhibitor. The N,N-dimethylation in N,N-DMPEA introduces steric hindrance around the nitrogen atom. While literature on the exact half-life of N,N-DMPEA in humans is scarce, structural activity relationship (SAR) principles suggest that this modification may alter its affinity for MAO enzymes, potentially extending its duration of action in the central nervous system compared to standard PEA, though it remains a relatively short-acting compound compared to alpha-methylated phenethylamines (like amphetamines).
### Trace Amine-Associated Receptor 1 (TAAR1) Agonism
The primary pharmacodynamic mechanism of N,N-DMPEA involves its action as an agonist at the Trace Amine-Associated Receptor 1 (TAAR1). TAAR1 is an intracellular G protein-coupled receptor (GPCR) predominantly expressed in monoaminergic regions of the brain, including the ventral tegmental area (VTA), substantia nigra, and raphe nuclei.
When N,N-DMPEA enters the presynaptic neuron (likely via passive diffusion or transport via monoamine transporters), it binds to and activates intracellular TAAR1. This activation triggers a signaling cascade involving adenylyl cyclase, leading to an increase in intracellular cyclic AMP (cAMP) and the subsequent activation of protein kinase A (PKA) and protein kinase C (PKC). These kinases phosphorylate the intracellular domains of monoamine transporters—specifically the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT).
Phosphorylation of these transporters induces a conformational change that reverses their direction of transport. Instead of clearing neurotransmitters from the synaptic cleft, the transporters begin to pump cytosolic dopamine and norepinephrine out of the neuron and into the synapse. This non-exocytotic release of catecholamines results in a rapid and pronounced increase in synaptic dopamine and norepinephrine concentrations, mediating the stimulant, euphoric, and focus-enhancing effects commonly reported by users of N,N-DMPEA.
### 5-HT1A Receptor Interaction
In addition to its effects on catecholamine release via TAAR1, N,N-DMPEA has been identified as a ligand for the 5-HT1A receptor. The 5-HT1A receptor is a subtype of serotonin receptor that functions both as a presynaptic autoreceptor (in the raphe nuclei) and as a postsynaptic heteroreceptor (in regions like the hippocampus and cortex).
Binding to the 5-HT1A receptor generally exerts an inhibitory effect on neuronal firing. As an autoreceptor, its activation decreases the firing rate of serotonergic neurons and reduces serotonin synthesis and release. The exact intrinsic activity of N,N-DMPEA at this receptor (whether it acts as a full agonist, partial agonist, or antagonist) requires further elucidation in human models. However, 5-HT1A agonism is classically associated with anxiolytic and mood-modulating effects. In the context of a stimulant, concurrent 5-HT1A interaction might serve to 'smooth out' the harshness of the dopamine and norepinephrine spike, potentially explaining why users often describe the energy from Eria Jarensis extracts as 'clean' or 'euphoric' rather than purely jittery.
### Hepatic Metabolism and CYP2D6 Interactions
The pharmacokinetics of N,N-DMPEA involve significant hepatic metabolism. Clinical data indicates a moderate to severe interaction between N,N-DMPEA and the Cytochrome P450 2D6 (CYP2D6) enzyme system. CYP2D6 is responsible for the metabolism and clearance of approximately 25% of all clinically used medications, including many antidepressants, antipsychotics, and analgesics.
N,N-DMPEA appears to interact with CYP2D6, potentially acting as a substrate that competitively inhibits the enzyme, or directly downregulating its activity. Consequently, the presence of N,N-DMPEA can decrease the rate at which the liver breaks down other CYP2D6 substrates. This pharmacokinetic bottleneck can lead to elevated plasma concentrations of co-administered drugs, significantly increasing the risk of adverse effects and toxicity. Medications affected by this pathway include amitriptyline, clozapine, codeine, desipramine, donepezil, fentanyl, fluoxetine, methadone, metoprolol, olanzapine, ondansetron, tramadol, and trazodone. The inhibition of CYP2D6 by a dietary supplement ingredient poses a substantial safety risk, particularly for individuals on psychiatric or cardiovascular medications.
### Botanical Origins vs. Synthetic Reality
N,N-DMPEA was originally isolated as a minor alkaloid from the orchid *Pinalia jarensis* (frequently referred to in the supplement industry by its synonym, *Eria jarensis*). In the plant, it likely serves as a secondary metabolite involved in defense mechanisms or pollinator attraction.
However, the concentrations of N,N-DMPEA found in natural orchid biomass are exceedingly low. The commercial reality of the sports nutrition industry dictates that extracting physiologically active doses of N,N-DMPEA from raw *Eria jarensis* would be economically unfeasible. Therefore, the vast majority of N,N-DMPEA found in pre-workout and weight loss supplements is synthetically manufactured. The use of the botanical name 'Eria Jarensis Extract' on supplement facts panels is often a regulatory and marketing maneuver designed to present a synthetic designer stimulant as a natural dietary ingredient, a practice that has drawn significant scrutiny from regulatory bodies following similar controversies with other orchid-derived claims (such as Dendrobium).
What is N dimethylphenethylamine used for? +
What are the risks of taking DMPEA? +
What are the benefits of phenylethylamine supplements? +
Is PEA supplement a stimulant? +
Does phenylethylamine interact with medications? +
What are the risks of using phenethylamines? +
Does phenylethylamine cause weight loss? +
What is Eria Jarensis? +
Is N,N-DMPEA natural or synthetic? +
How does N,N-DMPEA affect dopamine? +
Can N,N-DMPEA cause a false positive on a drug test? +
What is the half-life of N,N-DMPEA? +
Why is it compared to Dendrobium? +
Can I take N,N-DMPEA with antidepressants? +
Does N,N-DMPEA help with dry eyes? +
Is N,N-DMPEA safe for daily use? +
What is the difference between N,N-DMPEA and standard PEA? +
How does N,N-DMPEA interact with the liver? +
Everything About N,N-Dimethylphenylethylamine Article
## Introduction to N,N-Dimethylphenylethylamine (Eria Jarensis)
N,N-Dimethylphenylethylamine (N,N-DMPEA) is a chemical compound belonging to the phenethylamine class. In the world of sports nutrition and dietary supplements, it is most famously known by the name of the orchid from which it was originally isolated: *Eria Jarensis* (scientifically synonymous with *Pinalia jarensis*).
Originally utilized in minute quantities as a flavoring agent in the food industry—imparting a sweet, somewhat fishy aroma to cereals, dairy, and meats—N,N-DMPEA has recently surged in popularity as a potent stimulant in pre-workout powders and fat burners. Marketed as the next generation of euphoric energy enhancers, it is often touted as a legal alternative to banned substances like DMAA or ephedrine. However, despite its widespread use in the fitness community, the scientific literature surrounding its use in humans remains remarkably sparse.
## The Biochemistry of N,N-DMPEA
To understand how N,N-DMPEA works, one must look at its chemical structure. It is a derivative of phenylethylamine (PEA), a naturally occurring trace amine in the human brain that acts as a neuromodulator. Standard PEA is often called the 'love molecule' due to its ability to induce rapid euphoria; however, it is broken down almost instantly by the enzyme monoamine oxidase B (MAO-B), making it largely ineffective as an oral supplement.
N,N-DMPEA features two methyl groups attached to its nitrogen atom. This N,N-dimethylation provides steric hindrance, a structural shield that makes it more difficult for MAO-B to break the molecule down. While it is still metabolized relatively quickly compared to heavy-duty synthetic stimulants, this modification allows it to survive long enough to cross the blood-brain barrier and exert systemic effects.
Once in the brain, N,N-DMPEA acts as an agonist at the Trace Amine-Associated Receptor 1 (TAAR1). Activation of TAAR1 triggers the reversal of monoamine transporters, causing a flood of dopamine and norepinephrine into the synaptic cleft. This mechanism is responsible for the intense rush of energy, focus, and mood elevation reported by users. Furthermore, N,N-DMPEA acts as a ligand at the 5-HT1A serotonin receptor, which may contribute to a mood-smoothing effect, preventing the harsh, jittery feeling associated with pure adrenergic stimulants.
## Proposed Benefits and Uses
### Athletic Performance and Energy The primary reason consumers seek out N,N-DMPEA is for its stimulant properties. By increasing extracellular dopamine and norepinephrine, it primes the central nervous system for intense physical exertion. Users frequently report enhanced stamina, a higher threshold for pain during lifting, and a 'tunnel vision' level of focus. However, it is critical to note that according to medical authorities, there is currently insufficient scientific evidence to officially support its effectiveness for athletic performance.
### Weight Loss and Metabolism Like many stimulants, N,N-DMPEA is often included in thermogenic fat burners. The rationale is that increased norepinephrine release can stimulate lipolysis (the breakdown of fats) and increase resting metabolic rate. While the mechanism is biologically plausible, clinical trials verifying its efficacy for obesity or weight loss in humans do not exist.
### Dry Eye Relief Interestingly, outside of sports nutrition, early research has investigated the use of N,N-DMPEA in ophthalmology. Some data suggests that when applied directly to the eye via drops, it can improve the composition of tears in individuals suffering from dry eye syndrome. This application is highly specific and should not be conflated with oral ingestion.
## The 'Orchid Extract' Controversy in Sports Nutrition
The marketing of N,N-DMPEA as 'Eria Jarensis Extract' is a subject of intense regulatory debate. This practice mirrors a historical controversy in the supplement industry involving another orchid: Dendrobium.
In 2013, researchers at Harvard Medical School analyzed a wildly popular pre-workout supplement called Craze. The product claimed to derive its incredible stimulant effects from a natural Dendrobium orchid extract (listed as N,N-DEPEA). However, the analysis revealed the presence of N,alpha-DEPEA, a synthetic, unstudied designer drug structurally similar to methamphetamine. The researchers concluded that the amount of the active compound present could not possibly have been extracted from natural orchids, exposing the 'botanical extract' claim as a facade for synthetic adulteration.
Similarly, while N,N-DMPEA *does* exist in the *Pinalia jarensis* orchid, the concentrations are microscopic. To yield the 150mg to 250mg doses found in modern pre-workouts, an astronomical amount of raw plant material would be required, making natural extraction economically impossible. Therefore, consumers should be aware that the 'Eria Jarensis' in their supplements is almost certainly synthetically manufactured N,N-DMPEA.
## Safety, Side Effects, and Drug Interactions
The safety profile of N,N-DMPEA in medicinal or performance-enhancing doses is largely unknown. While it is considered 'Likely Safe' when used in trace amounts as a food flavoring, taking it in large doses by mouth is considered 'Possibly Unsafe.' There has been at least one reported case of a stroke in a woman who consumed a dietary supplement containing N,N-DMPEA alongside other ingredients, though direct causation is difficult to isolate in multi-ingredient formulas.
### The CYP2D6 Interaction One of the most significant safety concerns regarding N,N-DMPEA is its interaction with the liver enzyme Cytochrome P450 2D6 (CYP2D6). This enzyme is responsible for metabolizing a vast array of prescription medications. N,N-DMPEA has been shown to interact with CYP2D6, potentially decreasing the liver's ability to break down these drugs.
If you take medications metabolized by CYP2D6—such as SSRI antidepressants (fluoxetine), pain medications (tramadol, codeine), or antipsychotics (clozapine, olanzapine)—consuming N,N-DMPEA could cause these drugs to build up to toxic levels in your bloodstream, leading to severe adverse effects.
## Dosing and Supplementation Guidelines
Because of the lack of clinical trials, there is no medically established standard dose for N,N-DMPEA. In the sports nutrition market, products typically dose 'Eria Jarensis Extract' between 100mg and 250mg per serving. However, because natural products and synthetic designer stimulants are not always safe, and because individual tolerance to phenethylamines varies wildly, extreme caution is advised. Always consult with a healthcare professional before introducing novel stimulants into your regimen, especially if you are taking prescription medications.